Ophthalmic Diseases

Focusing on Sight

Our Focus

Wet Age-Related Macular Degeneration (Wet AMD)

Neovascular age-related macular degeneration (wet AMD) is a type of age-related macular degeneration where abnormal blood vessels (choroidal neovascularization or CNV) grow into the macula, the central area of the retina. As a result, CNV causes swelling of and fluid retention in the retina, bleeding, scarring, and causes blurry vision and reduced ability to see small details. The ongoing leaking of the abnormal blood vessels is stimulated by vascular endothelial growth factor otherwise known as VEGF. This process distorts and can potentially destroy central vision and may progress to blindness without treatment. Wet AMD is typically treated with intravitreal anti-VEGF agents administered approximately every 4-12 weeks.

Diabetic Macular Edema (DME)

People who have type 1 or type 2 diabetes may develop a complication called diabetic retinopathy or damage to the small blood vessels of the eye’s retina that can lead to vision loss. Diabetic macular edema (DME), which is associated with diabetic retinopathy and progresses faster, occurs when fluid from these damaged blood vessels leaks into the macula — an area in the center of the retina that helps us see objects directly ahead of us — which causes swelling of the retina and is also associated with vision loss. DME is typically treated with intravitreal anti-VEGF agents administered approximately every 4-12 weeks.

Geographic Atrophy (GA)

Geographic atrophy (GA) is a highly prevalent disease with a significant unmet medical need. It is estimated that there are approximately 2.5 million individuals with GA in the United States and major European markets, and an estimated 5 million individuals globally. GA is an advanced and severe form of age-related macular degeneration (AMD) that leads to irreversible vision loss. GA is characterized by atrophic lesions in the outer retina that affect central vision and lead to irreversible vision loss. Progressive loss of central vision leads to difficulties driving, reading, and completing basic daily tasks. As a result, GA has a major impact on quality of life. Complement-mediated inflammation is recognized as a main contributor to the development and worsening of GA. The only FDA approved treatments for GA are complement inhibitors administered by intravitreal (IVT) injection once every 4-9 weeks.

Ophthalmology Clinical Trials

About 4D-150 for the treatment of wet AMD & DME

4D-150 is being evaluated in the PRISM clinical trial, a Phase 1/2 dose-escalation and randomized, controlled, masked expansion study of intravitreal 4D-150 in adults with wet AMD. The primary endpoints of the study are safety and tolerability. Secondary endpoints include the number of supplemental aflibercept injections over 52 weeks and change from baseline in best corrected visual acuity (BCVA) and central subfield thickness (CST).

ClinicalTrials.gov

About 4D-150 for the treatment of wet AMD & DME

4D-150 is being evaluated in Part 1 of the SPECTRA clinical trial, a study of intravitreal 4D-150 genetic medicine in adults with DME. The primary endpoint of this study is the annualized number of aflibercept injections in the study eye. Secondary endpoints include safety and tolerability, change from baseline in BCVA, CST and percentage of subjects with improvement in the diabetic retinopathy severity scale.

ClinicalTrials.gov

Ophthalmic Diseases

Our Focus

Wet Age-Related Macular Degeneration (Wet AMD)

Diabetic Macular Edema (DME)

Geographic Atrophy (GA)

Ophthalmology Clinical Trials

About 4D-150 for the treatment of wet AMD & DME

About 4D-150 for the treatment of wet AMD & DME

About 4DMT

Navigation

Location